Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Mendus

    MCap

    SEK512m

    Last close

    SEK10.15

    ▲ 2.15 (26.88%)

    EML Payments

    MCap

    AUD251m

    Last close

    AUD0.67

    ▲ 0.06 (9.92%)

    SynBiotic

    MCap

    EUR32m

    Last close

    EUR6.66

    ▲ 0.48 (7.77%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Actinogen Medical (ASX: ACW)

Last close As at 24/10/2024

AUD0.03

— 0.00 (0.00%)

Market capitalisation

AUD80m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date.

Latest Insights

View More

Healthcare | Update

Actinogen Medical — A$11.1m capital raise completed

Healthcare | Update

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Healthcare | Flash note

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare | Update

Actinogen Medical — XanaCIDD data narrow the focus in depression
Actinogen Medical
Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.9) (62.0) 52.1
Relative (7.2) (63.3) 27.3
52 week high/low A$0.1/A$0.0

Financials

Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its previously disclosed A$8.1m share placement, total funds from the combined capital raising reached the targeted A$11.1m in gross proceeds. The company expects that the total proceeds will enable its operating runway to reach the release of top-line results for its XanaMIA Phase IIb/III trial in patients with mild-to-moderate Alzheimer’s disease (AD), expected in mid-CY26. The next major catalyst for Actinogen is the interim results on the first c 100 patients of this study, expected in mid-CY25, which could lead to licensing and/or value realisation opportunities. Our risk-adjusted net present value is A$619.8m (vs A$616.8m previously).

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2023A 4.9 (10.6) (8.9) (0.495) N/A N/A
2024A 9.9 (12.8) (11.4) (0.525) N/A N/A
2025E 7.3 (12.0) (11.5) (0.405) N/A N/A
2026E 14.1 (19.4) (19.4) (0.651) N/A N/A

Research

Update

Healthcare

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Flash note

Healthcare

Actinogen Medical — Further positive XanaCIDD results on depression

Healthcare

Update

Actinogen Medical — A$11.1m capital raise completed
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free